FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.
What happened
FDA inspected InvaDerm's drug manufacturing facility at 25 Worlds Fair Drive, Somerset, NJ, from October 15 to 17, 2024. After the inspection, FDA reviewed the company's drug listings and current labeling submitted in FDA's electronic Drug Registration and Listing System (eDRLS, the online database where firms register and list their drugs). FDA found the products are drugs because their labeling claims they treat or prevent disease or affect the body, that they are not generally recognized as safe and effective, and that no FDA-approved application is in effect for them.
What FDA found
The products are drugs because their labeling says they diagnose, cure, mitigate, treat or prevent disease, or affect the structure or function of the body.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128The products are "new drugs" because they are not generally recognized as safe and effective for the uses stated in their labeling.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)The products are marketed without an approved application (FDA's permission to sell a new drug), which the law requires.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The company introduces or delivers these unapproved drugs into interstate commerce.
Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)The company's drug listing information in eDRLS was not kept up to date.
21 CFR 207.30(a)(2)
What FDA wants
FDA tells the company to stop marketing all of the unapproved prescription drugs made at its facility immediately and to reply in writing within 15 working days describing the corrections and preventing recurrence, including progress on updating its eDRLS drug listing files.
Who should pay attention
- distributors and retailers that stock or sell this firm's drug products
- brands that buy finished drug products from this contract manufacturer
- regulatory staff responsible for drug listing data submitted to FDA
This is a summary. Read the original letter on fda.gov.